dc.contributor.author |
Hartl, Dominik |
|
dc.date.accessioned |
2025-01-28T10:12:51Z |
|
dc.date.available |
2025-01-28T10:12:51Z |
|
dc.date.issued |
2024 |
|
dc.identifier.issn |
1359-6446 |
|
dc.identifier.uri |
http://hdl.handle.net/10900/161258 |
|
dc.language.iso |
en |
de_DE |
dc.publisher |
London : Elsevier Sci Ltd |
de_DE |
dc.relation.uri |
http://dx.doi.org/10.1016/j.drudis.2024.104128 |
de_DE |
dc.subject.ddc |
610 |
de_DE |
dc.title |
Comparative analysis of FDA approvals by top 20 pharma companies (2014-2023) |
de_DE |
dc.type |
Article |
de_DE |
utue.quellen.id |
20241001000000_00349 |
|
utue.personen.roh |
Schuhmacher, Alexander |
|
utue.personen.roh |
Gassmann, Oliver |
|
utue.personen.roh |
Hinder, Markus |
|
utue.personen.roh |
Hartl, Dominik |
|
dcterms.isPartOf.ZSTitelID |
Drug Discovery Today |
de_DE |
dcterms.isPartOf.ZS-Issue |
Article 104128 |
de_DE |
dcterms.isPartOf.ZS-Volume |
29 (9) |
de_DE |
utue.fakultaet |
04 Medizinische Fakultät |
de_DE |